FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:995-1000 September 30, 1993 Number 14 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In patients with the acquired immunodeficiency syndrome (AIDS), toxoplasmic encephalitis is usually a presumptive diagnosis based on the clinical manifestations, a positive antitoxoplasma-antibody titer, and characteristic neuroradiologic abnormalities. A response to specific therapy helps to confirm the diagnosis, but it is unclear how rapid the response should be. We studied the course of patients treated for acute toxoplasmic encephalitis and evaluated objective clinical criteria for this empirical diagnosis.

Methods A quantifiable neurologic assessment was used prospectively to evaluate the clinical outcome of patients with AIDS and toxoplasmic encephalitis who were treated with oral clindamycin (600 mg four times a day) and pyrimethamine (75 mg every day) for six weeks.

Results Thirty-five of 49 patients (71 percent) responded to therapy, and 30 of these (86 percent) had improvement by day 7. Thirty-two of those with a response (91 percent) improved with respect to at least half of their base-line abnormalities by day 14. Improvement in neurologic abnormalities within 7 to 14 days after the start of therapy was strongly associated with the neurologic response at 6 weeks. The four patients in whom treatment failed and the two patients with lymphoma had progressing neurologic abnormalities or new abnormalities during the first 12 days of therapy. Nonlocalizing abnormalities (headache and seizure) improved regardless of the clinical outcome.

Conclusions Oral clindamycin and pyrimethamine are an effective treatment for toxoplasmic encephalitis. Patients who have early neurologic deterioration despite treatment or who do not improve neurologically after 10 to 14 days of appropriate antitoxoplasma therapy should be considered candidates for brain biopsy.

Source Information

From the State University of New York at Stony Brook (B.J.L., E.M.B., J.F.); the Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Md. (R.H.); Harvard School of Public Health, Boston (A.H.K., D.D.B.); Groupe Hospitalier Bichat-Claude Bernard, Paris (C.L., J.-L.V.); Los Angeles County-University of Southern California Medical Center, Los Angeles (D.A.); University of Miami, Miami (R.U.); Mount Sinai Medical Center, New York (J.J.); Hopital Pellegrin, Bordeaux, France (P.M.); and the Palo Alto Medical Foundation, Palo Alto, Calif. (J.S.R.) The contributing members of the Agence Nationale de Recherches sur le SIDA (ANRS) of the Institut National de la Sante et de la Recherche Medicale, the AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases, and the independent investigators are listed in the Appendix.

Address reprint requests to Dr. Luft at the Division of Infectious Diseases, State University of New York at Stony Brook, Stony Brook, NY 11794.

Full Text of this Article

This article has been cited by other articles:

• Denoeud, L., Pacanowski, J., Welker, Y., Moulignier, A., Girard, P.-M. (2008). Staphylococcus aureus Brain Abscess in an HIV-Infected Patient Exposed to Enfuvirtide. J Int Assoc Physicians AIDS Care (Chic Ill) 7: 217-219 [Abstract]  
• Di Cristina, M., Marocco, D., Galizi, R., Proietti, C., Spaccapelo, R., Crisanti, A. (2008). Temporal and Spatial Distribution of Toxoplasma gondii Differentiation into Bradyzoites and Tissue Cyst Formation In Vivo. Infect. Immun. 76: 3491-3501 [Abstract] [Full Text]  
• Fauquenoy, S., Morelle, W., Hovasse, A., Bednarczyk, A., Slomianny, C., Schaeffer, C., Van Dorsselaer, A., Tomavo, S. (2008). Proteomics and Glycomics Analyses of N-Glycosylated Structures Involved in Toxoplasma gondii-Host Cell Interactions. Mol. Cell. Proteomics 7: 891-910 [Abstract] [Full Text]  
• Kongsaengdao, S., Samintarapanya, K., Oranratnachai, K., Prapakarn, W., Apichartpiyakul, C. (2008). Randomized Controlled Trial of Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients. J Int Assoc Physicians AIDS Care (Chic Ill) 7: 11-16 [Abstract]  
• Davaro, R. E., Thirumalai, A. (2007). Life-Threatening Complications of HIV Infection. J Intensive Care Med 22: 73-81 [Abstract]  
• Martins-Duarte, E. S., Urbina, J. A., de Souza, W., Vommaro, R. C. (2006). Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro. J Antimicrob Chemother 58: 59-65 [Abstract] [Full Text]  
• Lee, C. W., Bennouna, S., Denkers, E. Y. (2006). Screening for Toxoplasma gondii-Regulated Transcriptional Responses in Lipopolysaccharide-Activated Macrophages. Infect. Immun. 74: 1916-1923 [Abstract] [Full Text]  
• Khan, A., Su, C., German, M., Storch, G. A., Clifford, D. B., Sibley, L. D. (2005). Genotyping of Toxoplasma gondii Strains from Immunocompromised Patients Reveals High Prevalence of Type I Strains. J. Clin. Microbiol. 43: 5881-5887 [Abstract] [Full Text]  
• Young, R. J., Ghesani, M. V., Kagetsu, N. J., DeRogatis, A. J. (2005). Lesion Size Determines Accuracy of Thallium-201 Brain Single-Photon Emission Tomography in Differentiating between Intracranial Malignancy and Infection in AIDS Patients. Am. J. Neuroradiol. 26: 1973-1979 [Abstract] [Full Text]  
• Gupta, N., Zahn, M. M., Coppens, I., Joiner, K. A., Voelker, D. R. (2005). Selective Disruption of Phosphatidylcholine Metabolism of the Intracellular Parasite Toxoplasma gondii Arrests Its Growth. J. Biol. Chem. 280: 16345-16353 [Abstract] [Full Text]  
• Domhan, S., Morath, C., Schnulle, P., Waldherr, R., Zeier, M. (2005). A generalized seizure in a renal allograft recipient. Nephrol Dial Transplant 20: 834-836 [Full Text]  
• Oktenli, C., Doganci, L., Ozgurtas, T., Araz, R.E., Tanyuksel, M., Musabak, U., Sanisoglu, S.Y., Yesilova, Z., Erbil, M.K., Inal, A. (2004). Transient hypogonadotrophic hypogonadism in males with acute toxoplasmosis: suppressive effect of interleukin-1{beta} on the secretion of GnRH. Hum Reprod 19: 859-866 [Abstract] [Full Text]  
• Robben, P. M., Mordue, D. G., Truscott, S. M., Takeda, K., Akira, S., Sibley, L. D. (2004). Production of IL-12 by Macrophages Infected with Toxoplasma gondii Depends on the Parasite Genotype. J. Immunol. 172: 3686-3694 [Abstract] [Full Text]  
• Ionita, C., Wasay, M., Balos, L., Bakshi, R. (2004). MR Imaging in Toxoplasmosis Encephalitis after Bone Marrow Transplantation: Paucity of Enhancement despite Fulminant Disease. Am. J. Neuroradiol. 25: 270-273 [Abstract] [Full Text]  
• Berger, J. R. (2003). Mass Lesions of the Brain in AIDS: The Dilemmas of Distinguishing Toxoplasmosis from Primary CNS Lymphoma. Am. J. Neuroradiol. 24: 554-555 [Full Text]  
• Su, C., Evans, D., Cole, R. H., Kissinger, J. C., Ajioka, J. W., Sibley, L. D. (2003). Recent Expansion of Toxoplasma Through Enhanced Oral Transmission. Science 299: 414-416 [Abstract] [Full Text]  
• Dzierszinski, F., Coppin, A., Mortuaire, M., Dewailly, E., Slomianny, C., Ameisen, J.-C., DeBels, F., Tomavo, S. (2002). Ligands of the Peripheral Benzodiazepine Receptor Are Potent Inhibitors of Plasmodium falciparum and Toxoplasma gondii In Vitro. Antimicrob. Agents Chemother. 46: 3197-3207 [Abstract] [Full Text]  
• Barragan, A., Sibley, L. D. (2002). Transepithelial Migration of Toxoplasma gondii Is Linked to Parasite Motility and Virulence. JEM 195: 1625-1633 [Abstract] [Full Text]  
• Donald, R. G. K., Allocco, J., Singh, S. B., Nare, B., Salowe, S. P., Wiltsie, J., Liberator, P. A. (2002). Toxoplasma gondii Cyclic GMP-Dependent Kinase: Chemotherapeutic Targeting of an Essential Parasite Protein Kinase. Eukaryot Cell 1: 317-328 [Abstract] [Full Text]  
• Baggish, A. L., Hill, D. R. (2002). Antiparasitic Agent Atovaquone. Antimicrob. Agents Chemother. 46: 1163-1173 [Full Text]  
• Hu, K., Roos, D. S., Murray, J. M. (2002). A novel polymer of tubulin forms the conoid of Toxoplasma gondii. JCB 156: 1039-1050 [Abstract] [Full Text]  
• Nare, B., Allocco, J. J., Liberator, P. A., Donald, R. G. K. (2002). Evaluation of a Cyclic GMP-Dependent Protein Kinase Inhibitor in Treatment of Murine Toxoplasmosis: Gamma Interferon Is Required for Efficacy. Antimicrob. Agents Chemother. 46: 300-307 [Abstract] [Full Text]  
• Johnson, L. L., Sayles, P. C. (2002). Deficient Humoral Responses Underlie Susceptibility to Toxoplasma gondii in CD4-Deficient Mice. Infect. Immun. 70: 185-191 [Abstract] [Full Text]  
• Roberts, C. W., Walker, W., Alexander, J. (2001). Sex-Associated Hormones and Immunity to Protozoan Parasites. Clin. Microbiol. Rev. 14: 476-488 [Abstract] [Full Text]  
• Freund, Y. R., Zaveri, N. T., Javitz, H. S. (2001). In Vitro Investigation of Host Resistance to Toxoplasma gondii Infection in Microglia of BALB/c and CBA/Ca Mice. Infect. Immun. 69: 765-772 [Abstract] [Full Text]  
• Purdy, B. D. (2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice 13: 475-498 [Abstract]  
• Caamano, J., Tato, C., Cai, G., Villegas, E. N., Speirs, K., Craig, L., Alexander, J., Hunter, C. A. (2000). Identification of a Role for NF-{kappa}B2 in the Regulation of Apoptosis and in Maintenance of T Cell-Mediated Immunity to Toxoplasma gondii. J. Immunol. 165: 5720-5728 [Abstract] [Full Text]  
• Almond, D. S., Szwandt, I. S. F., Edwards, G., Lee, M. G., Winstanley, P. A. (2000). Disposition of Intravenous Pyrimethamine in Healthy Volunteers. Antimicrob. Agents Chemother. 44: 1691-1693 [Abstract] [Full Text]  
• Dzierszinski, F., Popescu, O., Toursel, C., Slomianny, C., Yahiaoui, B., Tomavo, S. (1999). The Protozoan Parasite Toxoplasma gondii Expresses Two Functional Plant-like Glycolytic Enzymes. IMPLICATIONS FOR EVOLUTIONARY ORIGIN OF APICOMPLEXANS. J. Biol. Chem. 274: 24888-24895 [Abstract] [Full Text]  
• Rothova, A., Bosch-Driessen, L. E H, van Loon, N. H, Treffers, W F. (1998). Azithromycin for ocular toxoplasmosis. Br. J. Ophthalmol. 82: 1306-1308 [Abstract] [Full Text]  
• Mercier, C., Howe, D. K., Mordue, D., Lingnau, M., Sibley, L. D. (1998). Targeted Disruption of the GRA2 Locus in Toxoplasma gondii Decreases Acute Virulence in Mice. Infect. Immun. 66: 4176-4182 [Abstract] [Full Text]  
• Baldeweg, T., Catalan, J., Gazzard, B. G (1998). Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy. J. Neurol. Neurosurg. Psychiatry 65: 34-41 [Abstract] [Full Text]  
• Lowichik, A., Ruff, A. J. (1995). Topical Review: Parasitic Infections of the Central Nervous System in Children. Part II: Disseminated Infections. J Child Neurol 10: 77-87 [Abstract]  
• He, C. Y., Striepen, B., Pletcher, C. H., Murray, J. M., Roos, D. S. (2001). Targeting and Processing of Nuclear-encoded Apicoplast Proteins in Plastid Segregation Mutants of Toxoplasma gondii. J. Biol. Chem. 276: 28436-28442 [Abstract] [Full Text]